Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

Banerji, 2009, Heat shock protein 90 as a drug target: some like it hot, Clin Cancer Res, 15, 9, 10.1158/1078-0432.CCR-08-0132 Banerji, 2005, Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies, J Clin Oncol, 23, 4152, 10.1200/JCO.2005.00.612 Neckers, 2002, Hsp90 inhibitors as novel cancer chemotherapeutic agents, Trends Mol Med, 8, S55, 10.1016/S1471-4914(02)02316-X Nimmanapalli, 2001, Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts, Cancer Res, 61, 1799 Ochel, 2001, Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones, Cell Stress Chaperones, 6, 105, 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2 Sato, 2000, Modulation of Akt kinase activity by binding to Hsp90, Proc Natl Acad Sci USA, 97, 10832, 10.1073/pnas.170276797 Schulte, 1996, Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway, Mol Cell Biol, 16, 5839, 10.1128/MCB.16.10.5839 Smith, 1995, Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent, Mol Cell Biol, 15, 6804, 10.1128/MCB.15.12.6804 Xu, 2001, Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90, J Biol Chem, 276, 3702, 10.1074/jbc.M006864200 Blagosklonny, 2002, Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs, Leukemia, 16, 455, 10.1038/sj.leu.2402415 Glaze, 2005, Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance, Cancer Chemother Pharmacol, 56, 637, 10.1007/s00280-005-1000-9 Smith, 2005, Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models, Cancer Chemother Pharmacol, 56, 126, 10.1007/s00280-004-0947-2 Hollingshead, 2005, In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative, Cancer Chemother Pharmacol, 56, 115, 10.1007/s00280-004-0939-2 Eiseman, 2005, Et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts, Cancer Chemother Pharmacol, 55, 21, 10.1007/s00280-004-0865-3 Ramanathan, 2005, Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers, Clin Cancer Res, 11, 3385, 10.1158/1078-0432.CCR-04-2322 Ramanathan R, Egorin M, Erlichman C, et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: Final results. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22–26, 2007 [Abstr B212]. Simon, 1997, Accelerated titration designs for phase I clinical trials in oncology, J Natl Cancer Inst, 89, 1138, 10.1093/jnci/89.15.1138 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205 Chen, 2007, Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection, J Chromatogr B Analyt Technol Biomed Life Sci, 858, 302, 10.1016/j.jchromb.2007.08.022 Pacey S, Wilson R, Walton M, et al. A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007 [abstr PR-6]. Lancet, 2006, Phase 1, pharmacokinetic (PK), pharmacodynamic (PD) study of of the Hsp-90 inhibitor, KOS-1022 (17-DMAG), in patients with refractory hematological malignancies, J Clin Oncol, 24, 2081, 10.1200/jco.2006.24.18_suppl.2081 Miller, 2007, Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T), J Clin Oncol, 25, 1115, 10.1200/jco.2007.25.18_suppl.1115 Bristol-Myers Squibb. Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer. In: ClinicalTrials.gov. NLM Identifier: NCT00780000. http://www.clinicaltrials.gov/ct2/show/NCT00780000 [accessed on March 25, 2009]. Bristol-Myers Squibb. Phase 1 Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel. In: ClinicalTrials.gov. NLM Identifier: NCT00803556. http://www.clinicaltrials.gov/ct2/show/NCT00803556 [accessed on March 25, 2009]. Holdsworth, 2007, CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor, AJR Am J Roentgenol, 189, W324, 10.2214/AJR.07.2496 Niu, 2009, Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab, Eur J Nucl Med Mol Imaging, 36, 1510, 10.1007/s00259-009-1158-1 Smith-Jones, 2006, Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET, J Nucl Med, 47, 793 Eiseman, 2007, Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors, Clin Cancer Res, 13, 2121, 10.1158/1078-0432.CCR-06-2286 Elfiky, 2008, BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience, J Clin Oncol, 26, 2503, 10.1200/jco.2008.26.15_suppl.2503 Flaherty, 2008, First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or QD, J Clin Oncol, 26, 2502, 10.1200/jco.2008.26.15_suppl.2502